253
Kalaris Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
243
FY23:
188
FY24:
2.61
FY25:
119
(positive)
Change from FY21 to FY25
millions USD
FY21:
33.2
FY22:
34.0
FY23:
3.16
FY24:
3.56
FY25:
2.93
Total assets
Change from FY21 to FY25
millions USD
FY21:
287
FY22:
277
FY23:
191
FY24:
6.16
FY25:
122
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions USD
FY21:
37.9
FY22:
24.3
FY23:
28.4
FY24:
24.7
FY25:
9.71
(negative)
Change from FY21 to FY25
millions USD
FY21:
23.5
FY22:
28.2
FY23:
16.6
FY24:
32.1
FY25:
33.2
(positive)
Change from FY21 to FY25
millions USD
FY21:
225
FY22:
225
FY23:
146
FY24:
−96.6
FY25:
78.8
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
287
FY22:
277
FY23:
191
FY24:
–
FY25:
122
All amounts in millions USD